Interim results of an multicenter observational clinical study on treatment strategies for chronic lymphocytic leukemia/small lymphocytic lymphoma in Russia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis shows high survival rates in CLL/SLL patients, suggesting targeted therapy reduces progression risk.

Survival rates after 10 years for patients in the study reached 93.88%, indicating effective treatments available in clinical practice.
Progression-free survival (PFS) was 76.93% among first-line therapy patients after 5 years, highlighting the effectiveness of initial treatment strategies.
Cox models show targeting therapy significantly lowers progression risk, particularly in patients beyond the second treatment line.
Risk factors like TP53 mutation were identified but lacked statistical significance, emphasizing the need for careful therapy choice.

Poddubnaya et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark